Frazier Life Sciences
Investment Details
Investor Type
Venture Capital
Asset Class Focus
Venture Capital
Stage Focus
Seed, Early Stage, Series A, Series B, Growth, Late Stage, Pre-IPO
Geographical Focus
United States, United Kingdom, Canada, Germany, Japan, Australia, China, India, France, Italy, Denmark, Switzerland, Spain, South Korea, Netherlands, New Zealand, Sweden, Belgium, Norway, Finland
Industries Focus
- Healthcare
- Digital Health
- Pharmaceuticals
- Medical Devices
- Diagnostics
- Biotechnology
- Medical Research
- Regenerative Medicine
- Oncology
- Neurology
- Cardiology
- Endocrinology
- Infectious Diseases
- Immunology
- Rare Diseases
Investment Size:
5,000,000 to 50,000,000 USD
Investor Details Founded: 2005
Frazier Life Sciences is a venture capital firm specializing in investments in private and publicly traded companies that discover, develop, and commercialize innovative biopharmaceuticals. The firm manages over $3.9 billion in capital, including venture funds focusing on company creation and private companies, and a public fund focused on small and mid-cap public companies. Since 2005, over 60 Frazier Life Sciences portfolio companies, many of which were created or seeded by FLS, have completed IPOs or M&As. The Frazier Life Sciences team consists of over 40 professionals with deep expertise in biopharmaceuticals, primarily located in Menlo Park, California (headquarters), San Diego, Seattle, Boston, New York, and London.
Frazier Life Sciences invests globally in private and publicly traded companies that discover, develop, and commercialize innovative biopharmaceuticals. The firm has raised over $3.9 billion in capital, including venture funds focusing on company creation and private companies, and a public fund focused on small and mid-cap public companies. Since 2005, over 60 Frazier Life Sciences portfolio companies, many of which were created or seeded by FLS, have completed IPOs or M&As. The Frazier Life Sciences team consists of over 40 professionals with deep expertise in biopharmaceuticals, primarily located in Menlo Park, California (headquarters), San Diego, Seattle, Boston, New York, and London.
Frazier Life Sciences invests globally in private and publicly traded companies that discover, develop, and commercialize innovative biopharmaceuticals. The firm has raised over $3.9 billion in capital, including venture funds focusing on company creation and private companies, and a public fund focused on small and mid-cap public companies. Since 2005, over 60 Frazier Life Sciences portfolio companies, many of which were created or seeded by FLS, have completed IPOs or M&As. The Frazier Life Sciences team consists of over 40 professionals with deep expertise in biopharmaceuticals, primarily located in Menlo Park, California (headquarters), San Diego, Seattle, Boston, New York, and London.
Requirements
- Innovative biopharmaceutical companies addressing significant medical needs
- Strong management teams
- Potential for substantial growth and value creation
Contact
[Official Website Hidden]
[HQ Location Hidden]
[Email Hidden]
[Contact Number Hidden]
Portfolio Companies
- Alpine Immune Sciences
- Arcutis Biotherapeutics
- Mirum Pharmaceuticals
- NewAmsterdam Pharma
- Tarsus Pharmaceuticals
- Amunix Pharmaceuticals
- HilleVax
- Phathom Pharmaceuticals
- Scout Bio
- KalVista Pharmaceuticals
- Krystal Biotech
- Deciphera Pharmaceuticals
- Verona Pharma
- Syndax Pharmaceuticals
- BridgeBio Pharma
- Soleno Therapeutics
- Chinook Therapeutics
- Acerta Pharma
Mentioned In
Claim this Investor
Are you an official representative of Frazier Life Sciences?
Claim this investor to update information, manage your profile, and get a verified seal.
Claim